stockrow
Monday 9 November 2026
Export ADAG’s income statement to Excel — free account
Adagene Inc. Sponsored ADR
ADAGAdagene Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $7.7 million, up 7,333.0% from fiscal 2024.
2.00
0.02
−0.99%
Follow ADAG
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 0 | 1 | 10 | 9 | 18 | 0 | 8 | — | +58.7% | 2 | 5 | 5 | (16.3%) | |
| Gross margin, % | — | — | — | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | — | 0.0 pt | ||||||
| EBT | — | — | — | (16) | (42) | (71) | (80) | (17) | (33) | (18) | — | +1.4% | ||||||
| EBT margin, % | — | — | — | (3,423.40) | (6,048.98) | (702.45) | (855.65) | (95.27) | (32,404.75) | (233.44) | — | +3,190.0 pt | ||||||
| Net income | — | 0 | — | (42) | (42) | (73) | (80) | (19) | (33) | (18) | (81) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.04 | 0.05 | 0.25 | 0.21 | 0.33 | 0.00 | 0.13 | — | +22.0% | |||||
| Earnings | — | — | — | (1.35) | (2.67) | (1.46) | (1.48) | (0.35) | (0.59) | (0.30) | — | (22.2%) | ||||||
| Cash flow | — | — | — | (2.35) | (2.24) | (1.08) | (1.12) | (0.52) | (0.53) | (0.27) | 0.00 | (30.5%) | ||||||
| Capex | — | — | — | (0.08) | (0.07) | (0.06) | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 | (60.3%) | ||||||
| Free cash flow | — | — | — | (2.43) | (2.31) | (1.15) | (1.14) | (0.52) | (0.53) | (0.27) | 0.00 | (30.8%) | ||||||
| Book value | — | — | — | (4.69) | (7.00) | 3.91 | 1.92 | 1.29 | 0.90 | 0.60 | 0.00 | n/m | ||||||
| Shares, m | — | — | — | 12 | 13 | 40 | 43 | 55 | 56 | 59 | — | +30.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.0 | ||||||
| P/B | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | 0.00 | 0.00 | 0.00 | 0.89 | 0.65 | 0.59 | 1.04 | 1.77 | 0.5 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (29) | (29) | (43) | (49) | (28) | (30) | (16) | (71) | (9.5%) | |||||
| Capex | — | — | — | (1) | (1) | (3) | (1) | 0 | 0 | 0 | 0 | (49.3%) | ||||||
| Free cash flow | — | — | — | (29) | (29) | (46) | (49) | (29) | (30) | (16) | (71) | (10.0%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 97 | 63 | 156 | 94 | 82 | 50 | 52 | 106 | (9.8%) | |||||
| Net debt | — | — | — | (99) | (71) | (170) | (127) | (92) | (72) | (73) | (127) | (5.0%) | ||||||
| Shareholders’ equity | — | — | — | (57) | (89) | 157 | 83 | 71 | 51 | 35 | 89 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (31.50) | (44.85) | (53.48) | (46.78) | (14.13) | (32.61) | (21.02) | 0.00 | +10.5 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 22.78 | 58.26 | (217.98) | (66.74) | (24.66) | (55.21) | (41.01) | 0.00 | (63.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 198 | 259 | 248 | 174 | 138 | 128 | — | (8.4%) | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.04 | 0.04 | 0.10 | 0.00 | 0.06 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · fundamentals updated 25 Oct 2026
Adagene Inc. Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MSLE Satellos Bioscience Inc. | $152.6M | — (loss-making) | — | — | n/m | −65.66% (below 0%: shrinking) | 99.26% | 0.00% | Compare |
| MGNX MacroGenics, Inc. | $148.4M | — (loss-making) | — (loss-making) | +47.62% (above 0%: growing) | n/m | +12.88% (above 0%: growing) | 100.00% | (42.19%) | Compare |
| SION Sionna Therapeutics, Inc. | $148.3M | — (loss-making) | — | — | n/m | −22.40% (below 0%: shrinking) | — | 0.00% | Compare |
| YARW Yarrow Bioscience, Inc | $147.2M | — (loss-making) | — (loss-making) | +40.58% (above 0%: growing) | n/m | +81.56% (above 0%: growing) | 100.00% | (3,197.94%) | Compare |
| NGEN NervGen Pharma Corp. | $143.1M | — (loss-making) | — | — | n/m | −48.10% (below 0%: shrinking) | — | 0.00% | Compare |
| VRXA Veraxa Biotech AG | $140.4M | — | — | — | — | — | — | — | Compare |
| CUE Cue Biopharma, Inc. | $136.1M | — (loss-making) | — (loss-making) | +166.66% (above 0%: growing) | n/m | −742.65% (below 0%: shrinking) | 100.00% | (1,113.30%) | Compare |
| TARA Protara Therapeutics, Inc. | $135.9M | — (loss-making) | — | — | n/m | −28.10% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ADAG Adagene Inc. Sponsored ADR | $134.3M | — | — (loss-making) | — | — | −11.08% (below 0%: shrinking) | — | — | |
| Median of peers | $145.2M | — | — | +47.62% | — | −28.10% | 100.00% | 0.00% |